drugset / Trial / NCT03768037
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.
Timeline
- Start
- 2018-11-26
- Primary completion
- 2019-11-26
- Completion
- 2020-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |